Abstract
We report a case of therapy-related acute myeloid leukemia (t-AML), M4 FAB subtype, with t(10;11)(p14;q21) chromosome abnormality developed in a patient treated for acute promyelocytic leukemia (APL) after 4 years of continuous complete remission (CCR). Two distinct forms of t-AML have been described: the classical type and the second type. Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase. However, it differs in the chromosome 11 breakpoint (band q21 instead of q23) and absence of ALL-1 (Hrx, MLL, Htrx) gene involvement. This can represent the second observation of t-AML occurring after treatment for APL.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Chromosomes, Human, Pair 10 / genetics*
-
Chromosomes, Human, Pair 11 / genetics*
-
Chromosomes, Human, Pair 15
-
Chromosomes, Human, Pair 17
-
Cytarabine / adverse effects
-
Etoposide / adverse effects
-
Female
-
Humans
-
Idarubicin / adverse effects
-
Karyotyping
-
Leukemia, Myelomonocytic, Acute / chemically induced*
-
Leukemia, Myelomonocytic, Acute / drug therapy
-
Leukemia, Myelomonocytic, Acute / genetics
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukemia, Promyelocytic, Acute / genetics
-
Mercaptopurine / adverse effects
-
Methotrexate / adverse effects
-
Mitoxantrone / adverse effects
-
Neoplasms, Second Primary / chemically induced*
-
Neoplasms, Second Primary / drug therapy
-
Neoplasms, Second Primary / genetics
-
Remission Induction
-
Thioguanine / adverse effects
-
Translocation, Genetic*
Substances
-
Cytarabine
-
Etoposide
-
Mitoxantrone
-
Mercaptopurine
-
Thioguanine
-
Methotrexate
-
Idarubicin